Skip to content

Efficacy and safety of endoscopic balloon dilatation combined with autologous platelet-rich plasma (PRP) injection in colonic stenosis in Crohn's disease

Efficacy and safety of endoscopic balloon dilatation combined with autologous platelet-rich plasma (PRP) injection in colonic stenosis in Crohn's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078304
Enrollment
Unknown
Registered
2023-12-04
Start date
2023-12-15
Completion date
Unknown
Last updated
2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease

Interventions

experimental group 1:endoscopic balloon dilatation combined with low concerntration autologous platelet-rich plasma (PRP) injection
experimental group 2:endoscopic balloon dilatation combined with hign concerntration autologous platelet-rich plasma (PRP) injection
historical control:NA

Sponsors

The Sixth Affiliated Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: ? Diagnosed as CD; ? Stenosis of the colon was found during colonoscopy, and surgery was not considered for the time being; ? Imaging stenosis was found, that is, CTE suggested stenosis with proximal intestinal dilatation >3cm; ? Narrow length <5cm; ? The patients agreed to undergo endoscopic balloon dilatation and voluntarily signed the informed consent to participate in this study, and were capable of complying with the agreement.

Exclusion criteria

Exclusion criteria: ? The patient has contraindications for endoscopic therapy, such as coagulation disorder, severe cardiopulmonary dysfunction, active bleeding, and inability to cooperate. ? Deep and large active ulcer was found in the stenosis; ?< 18 years old; ? Foreign patients; ? Patients with a history of malignant tumors, including melanoma (except local skin cancer); ? Pregnant or nursing patients; ? Patients who could not be followed at all nodes of the primary outcome indicator; Other diseases that researchers believe could put patients at risk; ? Other diseases that researchers believe could put patients at risk.

Design outcomes

Primary

MeasureTime frame
restenosis rate;

Secondary

MeasureTime frame
Changes in intestinal ultrasound;Proportion of surgery;

Countries

China

Contacts

Public ContactYi Lu

The Sixth Affiliated Hospital, Sun Yat-sen University

luyifl@163.com+86 137 9435 3637

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026